

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6184290

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
YAIR ALSTER	06/23/2015
OMER RAFAELI	06/23/2015
KIRSTEN ANGELA MACFARLANE	06/24/2015
CARY REICH	07/06/2015
SHIMON AMSELEM	07/09/2015
DORON FRIEDMAN	06/23/2015
RECEIVING PARTY DATA	
Name:	M.G. THERAPEUTICS LTD.
Street Address:	69 BUGRASHOV STREET
City:	TEL AVIV
State/Country:	ISRAEL
Postal Code:	6342909
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16919749
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 493-9300
Email:	patentdocket@wsgr.com, randico@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	46968-701.304
NAME OF SUBMITTER:	ROSE ANDICO
SIGNATURE:	/Rose Andico/
DATE SIGNED:	07/02/2020
Total Attachments: 5	

source=46968-701.304 Executed Assignment (copy from parent application)#page1.tif
source=46968-701.304 Executed Assignment (copy from parent application)#page2.tif
source=46968-701.304 Executed Assignment (copy from parent application)#page3.tif
source=46968-701.304 Executed Assignment (copy from parent application)#page4.tif
source=46968-701.304 Executed Assignment (copy from parent application)#page5.tif

PATENT ASSIGNMENT

Docket Number 46968-701.201

WHEREAS, the undersigned:

- | | | | |
|---|---|--|---|
| 1. Yair ALSTER
46 Eshilat Warsaw Street
Tel Aviv 6970237 ISRAEL | 2. Omer RAFAELI
POB 447
Udim 4290509 ISRAEL | 3. Kirsten Angela
MACFARLANE
173 Jefferson Drive
Menlo Park, California 94025 | 4. Cary REICH
114 Ayala Court
Los Gatos, California 95032 |
| 5. Shimon AMSELEM
10 Miriam Mizrahi Street
Rehovot 7655156 ISRAEL | 6. Doron FRIEDMAN
33 Alon Street
Carne-Yosef 99797 ISRAEL | | |

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION

- for which a United States patent application is executed on even date herewith;
- for which application serial number 14/732,622 was filed on June 5, 2015 in the U.S. Patent and Trademark Office;
- for which application serial number _____ was filed on _____ in the U.S. Receiving Office of the Patent Cooperation Treaty;
- for which application serial number _____ was filed on _____ in the _____ Patent Office; and/or
- for which an application was filed upon which a United States Patent issued on _____ as U.S. Patent No. _____

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, M. G. Therapeutics, Ltd., a corporation having a place of business at 69 Bugrashov Street, Tel Aviv, 6342909 ISRAEL, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions, provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT

Docket Number 46968-701.201

IN WITNESS WHEREOF, said inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:


Date: 23.6.2015 Yair ALSTER Date: _____ Omer RAFAELI

Date: _____ Kirsten Angela MACFARLANE Date: July 6, 15 Cary KERN

Date: _____ Simon AMSELEM Date: _____ Doron FRIEDMAN

RECEIVED AND AGREED TO BY ASSIGNEE:

Date: 23.6.2015

By:  M.G. Therapeutics Ltd.
Name: Dr. Yair Alster
Title: Chief Executive Officer
M.G. Therapeutics, Ltd.

PATENT ASSIGNMENT

Docket Number 46966-701.261

IN WITNESS WHEREOF, said inventor(s) have executed and delivered this instrument to said Assignor as of the dates written below:

Date: 23.6.2015

Yair ALSTER

Date:

Omer RAFAELI

Date: 24 June 2015

Kristen Angela MACTABLANE

Date:

Cory REICH

Date:

Shimon ANSHELEM

Date:

Doreen FRIEDMAN

RECEIVED AND AGREED TO BY ASSIGNEE:

Date:

23.6.2015

By:

Name: Dr. Yair Alster
Title: Chief Executive Officer
M. G. Therapeutics Ltd.

M.G. Therapeutics Ltd.

PATENT ASSIGNMENT

Docket Number 46968-701.201

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: <u>23.6.2015</u>	<u>[Signature]</u> Yair ALSTER	Date: _____	<u>[Signature]</u> Omer KARAEI
Date: _____	Kirsten Angela MACFARLANE	Date: _____	Cary REICH
Date: _____	Shimon AMSELEM	Date: _____	Doron FRIEDMAN

RECEIVED AND AGREED TO BY ASSIGNEE:

Date: 23.6.2015

By: [Signature]
Name: Dr. Yair Alster
Title: Chief Executive Officer
M. G. Therapeutics, Ltd

M.G. Therapeutics Ltd.

PATENT ASSIGNMENT

Docket Number 46968-701.201

IN WITNESS WHEREOF, said inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below.

Date 7-30-2015

Yair ALSTER

Date

Omer RAFAELI

Date

Kirsten Angela MACARLANE

Date

Cary REICH

Date

July 9, 2015

Simon AMSELEM

Date

Doron FRIEDMAN

RECEIVED AND AGREED TO BY ASSIGNEE:

Date

7-30-2015

By

Name: Dr. Yair Alster
Title: Chief Executive Officer
M. G. Therapeutics, Ltd.

M.G. Therapeutics Ltd.